Jadenu® Sprinkle (deferasirox) – New formulation approval
May 18, 2017 – The FDA approved Novartis’ Jadenu Sprinkle (deferasirox) oral granules, for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients ≥ 2 years old, and for the treatment of chronic iron overload in patients ≥ 10 years old with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 mg of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.
Top